Source page: McKinsey & Company
June 17, 2025
Healthcare | Life Sciences
Glucagon-like peptide-1 (GLP-1) agonists have effectively helped patients lose weight and, consequently, are also changing their appearance.
Glucagon-like peptide-1 (GLP-1) agonists have effectively helped patients lose weight and, consequently, are also changing their appearance. As a result, it’s piquing patients’ interest in facial aesthetic procedures. In a recent McKinsey survey, US medical aesthetic providers are enthusiastic about developing therapies tailored specifically to these patients, note Senior Partner Nils Peters and colleagues. Interest in combination therapies lead the pack, with 70 percent of respondents expressing excitement, followed by injectable exosomes (64 percent) and radiofrequency microneedling (52 percent).
Chart family: Scatter Plot · Scatter Plot Customization
To read the article, see “GLP-1s are boosting demand for medical aesthetics,” May 15, 2025.
The preview updates when you finish a field or release a slider. Saving only stores this page’s widget settings and spreadsheet data in this browser and does not write back to WordPress.